Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2011 Filed Dec 1, 2011 19:12 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 319 | $36.34 | $11,592.46 |
DisclosureSEC source: 0001209191-11-058697 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,393 Read SEC document |
| November 18, 2011 Filed Nov 21, 2011 22:05 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
SaleCommon Stock | 5,000 | $36.88 | $184,400.00 |
DisclosureSEC source: 0001209191-11-057397 · doc4.xml · nonDerivative · entry 1 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,541 Read SEC document |
| November 17, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 13,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 8 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,375 Read SEC document |
| November 16, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 2,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 7 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,982 Read SEC document |
| November 11, 2011 Filed Nov 14, 2011 17:08 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,700 | $37.55 | $214,035.00 |
DisclosureSEC source: 0001209191-11-055635 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,053 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. Read SEC document |
| November 02, 2011 Filed Feb 3, 2012 00:12 UTC |
ARMITAGE ROBERT ASr. VP and General Counsel
|
GiftCommon Stock | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007191 · doc5.xml · nonDerivative · entry 1 ARMITAGE ROBERT A · CIK 0001233249 · Sr. VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · Robert A. Armitage 2008. 10-3 GRAT Disclosed balance after: 0 F1 · ownership.direct: Grantor retained annuity trust established by reporting person. Reporting person is trustee. Read SEC document |
| October 31, 2011 Filed Nov 2, 2011 14:19 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 224 | $38.29 | $8,576.96 |
DisclosureSEC source: 0001209191-11-053767 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,068 Read SEC document |
| October 31, 2011 Filed Dec 1, 2011 19:05 UTC Amendment |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 226 | $37.97 | $8,581.22 |
DisclosureSEC source: 0001209191-11-058694 · doc4a.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,074 F1 · shares: This amendment is being filed to correct the number of securities reported as acquired on the original Form 4 filed on 11/2/11; 2 shares were inadvertently omitted from the total. Read SEC document |
| October 11, 2011 Filed Oct 13, 2011 15:36 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,700 | $38.10 | $217,170.00 |
DisclosureSEC source: 0001209191-11-051643 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,753 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.05 to $38.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2011 Filed Jan 6, 2012 16:10 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,880 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-002446 · doc4.xml · derivative · entry 6 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 0 Underlying: Common Stock · 1,880 shares Expires 2011-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2011 Filed Jan 6, 2012 16:10 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Tax withholdingCommon Stock | 592 | $36.97 | $21,886.24 |
DisclosureSEC source: 0001209191-12-002446 · doc4.xml · nonDerivative · entry 2 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 1,288 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 02, 2011 Filed Jan 6, 2012 16:10 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Exercise / conversionCommon Stock | 1,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-002446 · doc4.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 1,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| October 01, 2011 Filed Oct 3, 2011 21:02 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-049744 · doc4.xml · derivative · entry 6 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2011-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2011 Filed Oct 3, 2011 21:02 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
Tax withholdingCommon Stock | 5,107 | $36.97 | $188,805.79 |
DisclosureSEC source: 0001209191-11-049744 · doc4.xml · nonDerivative · entry 3 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,541 Read SEC document |
| October 01, 2011 Filed Oct 3, 2011 21:02 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-049744 · doc4.xml · nonDerivative · entry 2 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2011 Filed Sep 30, 2011 17:18 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 227 | $37.81 | $8,582.87 |
DisclosureSEC source: 0001209191-11-049476 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,844 Read SEC document |
| September 30, 2011 Filed Dec 1, 2011 19:02 UTC Amendment |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 229 | $37.52 | $8,592.08 |
DisclosureSEC source: 0001209191-11-058692 · doc4a.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,848 F1 · shares: This amendment is being filed to correct the number of securities reported as acquired on the original Form 4 filed on 9/30/11; 4 shares were inadvertently omitted from the total. Read SEC document |
| September 12, 2011 Filed Sep 14, 2011 14:45 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,700 | $35.91 | $204,687.00 |
DisclosureSEC source: 0001209191-11-047782 · doc4.xml · nonDerivative · entry 2 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,453 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. Read SEC document |
| September 12, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 4,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 6 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,822 Read SEC document |
| August 31, 2011 Filed Aug 31, 2011 14:11 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 240 | $35.77 | $8,584.80 |
DisclosureSEC source: 0001209191-11-046080 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,459 Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 18:06 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,278 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-046262 · doc4.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,278 shares Expires 2011-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 18:06 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
Exercise / conversionCommon Stock | 3,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-046262 · doc4.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 18:06 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
Tax withholdingCommon Stock | 1,340 | $37.17 | $49,807.80 |
DisclosureSEC source: 0001209191-11-046262 · doc4.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,778 Read SEC document |
| August 26, 2011 Filed Sep 14, 2011 14:45 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
GiftCommon Stock | 145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-047782 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,153 Read SEC document |
| August 11, 2011 Filed Aug 12, 2011 18:47 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,700 | $33.94 | $193,458.00 |
DisclosureSEC source: 0001209191-11-043960 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,298 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.90 to $34.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2011 Filed Aug 3, 2011 16:13 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 226 | $38.05 | $8,599.30 |
DisclosureSEC source: 0001209191-11-042214 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,219 Read SEC document |
| July 22, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 5 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,048 Read SEC document |
| July 11, 2011 Filed Jul 13, 2011 18:36 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,700 | $37.39 | $213,123.00 |
DisclosureSEC source: 0001209191-11-039364 · doc4.xml · nonDerivative · entry 3 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,998 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.35 to $37.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2011 Filed Jul 8, 2011 19:20 UTC |
Deane Frank MPresident, Mfg. Operations
|
SaleCommon Stock | 5,000 | $37.20 | $186,000.00 |
DisclosureSEC source: 0001209191-11-038875 · doc4.xml · nonDerivative · entry 1 Deane Frank M · CIK 0001401222 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,124 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2011. Read SEC document |
| July 01, 2011 Filed Jul 13, 2011 18:36 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
GiftCommon Stock | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-039364 · doc4.xml · nonDerivative · entry 2 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,698 Read SEC document |
| June 30, 2011 Filed Jul 1, 2011 12:56 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 229 | $37.56 | $8,601.24 |
DisclosureSEC source: 0001209191-11-036992 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,993 Read SEC document |
| June 28, 2011 Filed Jul 13, 2011 18:36 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
GiftCommon Stock | 55 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-039364 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,252 Read SEC document |
| June 27, 2011 Filed Jun 28, 2011 18:52 UTC |
Deane Frank MPresident, Mfg. Operations
|
SaleCommon Stock | 3,300 | $36.73 | $121,209.00 |
DisclosureSEC source: 0001209191-11-036561 · doc4.xml · nonDerivative · entry 2 Deane Frank M · CIK 0001401222 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,124 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2011. Read SEC document |
| June 27, 2011 Filed Jun 28, 2011 18:52 UTC |
Deane Frank MPresident, Mfg. Operations
|
SaleCommon Stock | 1,700 | $36.74 | $62,458.00 |
DisclosureSEC source: 0001209191-11-036561 · doc4.xml · nonDerivative · entry 1 Deane Frank M · CIK 0001401222 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,424 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2011. Read SEC document |
| June 20, 2011 Filed Jun 22, 2011 19:06 UTC |
Deane Frank MPresident, Mfg. Operations
|
SaleCommon Stock | 5,000 | $37.38 | $186,900.00 |
DisclosureSEC source: 0001209191-11-035902 · doc4.xml · nonDerivative · entry 1 Deane Frank M · CIK 0001401222 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,124 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2011. Read SEC document |
| June 13, 2011 Filed Jun 15, 2011 13:45 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,700 | $37.25 | $212,325.00 |
DisclosureSEC source: 0001209191-11-034699 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,307 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.20 to $37.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2011 Filed Jun 2, 2011 19:23 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 219 | $39.15 | $8,573.85 |
DisclosureSEC source: 0001209191-11-032475 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,615 Read SEC document |
| May 19, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 669 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 10 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 54,242 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| May 19, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 669 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 4 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,109 Read SEC document |
| May 17, 2011 Filed May 18, 2011 18:01 UTC |
HANISH ARNOLD CChief Accounting Officer
|
SaleCommon Stock | 3,378 | $39.12 | $132,147.36 |
DisclosureSEC source: 0001209191-11-029286 · doc4.xml · nonDerivative · entry 2 HANISH ARNOLD C · CIK 0001233253 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,045 Read SEC document |
| May 13, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 16,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 3 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,778 Read SEC document |
| May 11, 2011 Filed May 13, 2011 13:15 UTC |
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 5,700 | $38.21 | $217,797.00 |
DisclosureSEC source: 0001209191-11-028166 · doc4.xml · nonDerivative · entry 1 Carmine Bryce D. · CIK 0001430788 · EVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,007 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.18 to $38.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2011 Filed May 18, 2011 18:01 UTC |
HANISH ARNOLD CChief Accounting Officer
|
GiftCommon Stock | 243 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-029286 · doc4.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,423 Read SEC document |
| May 06, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 672 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 9 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 54,911 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| May 06, 2011 Filed Feb 3, 2012 00:16 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 672 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-007193 · doc5.xml · nonDerivative · entry 2 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,467 Read SEC document |
| April 29, 2011 Filed May 2, 2011 18:35 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 241 | $35.62 | $8,584.42 |
DisclosureSEC source: 0001209191-11-025276 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,396 Read SEC document |
| April 20, 2011 Filed May 18, 2011 18:38 UTC |
Nobles AnneChief Eth/Cmpl Ofcr & SVP, ERM
|
SaleCommon Stock | 12,000 | $35.98 | $431,760.00 |
DisclosureSEC source: 0001209191-11-029324 · doc4.xml · nonDerivative · entry 1 Nobles Anne · CIK 0001462543 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,937 Read SEC document |
| April 12, 2011 Filed Oct 3, 2011 21:02 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GiftCommon Stock | 3,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-049744 · doc4.xml · nonDerivative · entry 4 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 18,206 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| April 12, 2011 Filed Oct 3, 2011 21:02 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GiftCommon Stock | 3,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-049744 · doc4.xml · nonDerivative · entry 1 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,148 Read SEC document |
| April 12, 2011 Filed Dec 20, 2011 18:30 UTC Amendment |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GiftCommon Stock | 3,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-062274 · doc4a.xml · nonDerivative · entry 2 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 18,115 F1 · shares: This amendment is being filed to correct the number of securities reported as gifts on the original Form 4 filed on 10/3/11; a difference of 91 shares was inadvertently reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.